CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol

Discovery ofN-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors

(2010) Shudong Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

(2009) K. F. Byth et al.   MOLECULAR CANCER THERAPEUTICS

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

(2008) C. Pepper et al.   BLOOD

The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation

(2008) Sonja Baumli et al.   EMBO JOURNAL

Targeting apoptosis: selected anticancer strategies

(2008) Shane Storey   NATURE REVIEWS DRUG DISCOVERY

Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology

(2008) S WANG et al.   TRENDS IN PHARMACOLOGICAL SCIENCES